Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | La Merie | Competitor Analysis: CHK and KSP - Eg5 Inhibitors

Competitor Analysis: CHK and KSP-Eg5 Inhibitors

The present Competitive Intelligence Report about checkpoint kinase (CHK) and kinesin spindle protein (KSP) or Eg5 inhibitors provides a competitor evaluation in the field of novel molecular entities inhibiting CHK or KS/Eg5 for treatment of cancer as of August 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Progression through the cell cycle is monitored by surveillance mechanisms known as cell cycle checkpoints. Dysfunction in cell cycle checkpoints leads to genomic instability and contributes to tumor progression. Checkpoint kinase 1 (CHK-1) plays a critical role in the activation of mitotic spindle checkpoint and DNA damage checkpoint. CHK-1) has become an oncology target of significant current interest. Inhibition of CHK-1 abrogates DNA damage-induced cell cycle checkpoints and might provide therapeutic benefit. At least seven different checkpoint kinase inhibitors are in early clinical development to evaluate its role in cancer therapy. Current evidence suggests that CHK inhibitors will be most successful when combined with chemotherapy or radiotherapy.

Mitotic kinesin inhibitors target Eg5, a member of the kinesin superfamily, which plays a key role in mitosis, as it is required for the formation of a bipolar spindle. Eg5 is also known as kinesin spindle protein (KSP). At least seven different small molecules are in early clinical development. Experience with ispinesib suggested that most value of Ek5 inhibition might be found in metastatic breast, ovarian and non-small cell lung cancer, whereas experience with other Eg5 inhibitors found more value in hematologic malignancies.

The report includes a compilation of current active projects in research and development of CHK and KSP/Eg5 inhibitors in oncology. In addition, the report lists company-specific R&D pipelines of CHK and KSP/Eg5 inhibitors. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

Index

CHK Inhibitors

E2F Pathway modulators

KSP/Eg5 Inhibitors

Corporate CHK and KSP/Eg5 Inhibitor R&D Pipelines

About La Merie

About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Publisher: La Merie

Product Line: Competitor Analysis

Pages: 19

Release Date: August of 2009

Format: PDF

Product Code: LMCA0077

License

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions